Liver stiffness measurement using FibroScan (Echosens, Paris, France) is a novel rapid and non-invasive technique that evaluates liver fibrosis. Two recent reports have shown that liver stiffness measurement using FibroScan allowed accurate prediction of hepatic fibrosis in patients with chronic hepatitis C virus infection [1, 2] . In patients with chronic hepatitis C, liver stiffness measurements ranged from 2.4 to 75 kPa with a median value of 7.4 kPa [2, 3] .
As previously described, FibroScan is placed in the intercostal position and a value of liver stiffness is obtained by pressing a button [4] . In some cases, however, no elasticity measurement is obtained: the acquisition system automatically rejects all elasticity estimates because they did not satisfy the criterion on linear regression coefficient of determination (r2) superior to 0.85 [4] . The criterion rejects the acquisitions if the elastic wave propagation is not measured properly.
The aim of this prospective study was to assess the prevalence and factors associated with failure of liver stiffness measurement in a large series of patients with chronic liver disease.
From May 2003 to April 2005, all patients with chronic liver disease and liver stiffness measurement were included. Failure of liver stiffness measurement was defined as no value obtained after 10 measurements. Clinical and biological factors associated with failure were analyzed using chi-square analysis and logistic regression.
Two thousand one hundred and fourteen liver stiffness measurements were analyzed. FibroScan examinations were performed by four operators. Clinical characteristics of the patients were as follow: 1168 men, mean age 52 ± 13 years, body mass index 24.4 ± 4.4 (range, 12-49), and diabetes 9.6%. Indications for FibroScan were hepatitis C virus (55.5%), hepatitis B virus (5.5%), alcohol (9%), nonalcoholic steatohepatitis (3.6%), hemochromatosis (2.4%), and miscellaneous (24%). The median value of FibroScan was 6.8 kPa (range, 1.5-75 kPa). Biological characteristics of the patients were as follows: alanine aminotransferase 74.9 ± 2.1 IU/l, aspartate aminotransferase 55.9 ± 1.7 IU/l, and g-glutamyl-transpeptidase 122.7 ± 4.7 IU/l.
Failure was observed in 96 cases (4.5%). By univariate analysis, factors associated with failure are presented in Table 1 . Failure was not associated with operator, gender or transaminase level. By multivariate analysis, the only factor associated with failure was body mass index greater than 28 (odds ratio, 10.0; 95% confidence interval, 5.7-17.9; P = 0.001).
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Liver stiffness measurement is feasible in more than 95% of cases. The liver stiffness measurement was not evaluated in patients with ascites since ascites is a physical limitation to the technique. Indeed, elastic waves do not propagate through liquids. The presence of ascites, however, generally indicates cirrhosis by itself and no non-invasive evaluation of liver fibrosis is needed.
Body mass index was the only factor associated with failure of FibroScan. In overweight or obese patients, the fatty thoracic belt attenuates both elastic waves and ultrasound, rendering liver stiffness measurement impossible. In these cases no results are obtained with FibroScan, preventing the risk of false measurement. In Western populations, where obesity is more prevalent, the failure rate could be greater. Specific probes therefore have to be developed for obese patients.
In conclusion, liver stiffness is a good method for the evaluation of liver fibrosis, which is feasible in more than 95% of patients. Other non-invasive methods such as biochemical methods or liver biopsy could be used in patients with failure of FibroScan examination. 
